Azacitidine 25 mg/ml powder for suspension for injection

DRUG2 trials

Sponsors

Syros Pharmaceuticals Inc., Groupe Francophone Des Myelodysplasies, Groupe Francophone Des Myelodysplasies

Conditions

Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndromemyelodysplastic syndrome with IDH1 mutated

Phase 2

IDIOME study: A single-arm phase II multicenter study of IDH1 (AG-120) inhibitor in patients with IDH1 mutated Myelodysplastic Syndrome

Active, not recruitingCTIS2024-515352-20-00

Groupe Francophone Des Myelodysplasies, Groupe Francophone Des Myelodysplasiesmyelodysplastic syndrome with IDH1 mutated

Start: 2019-03-20Target: 48Updated: 2024-08-02

Phase 3

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome

CompletedCTIS2023-510361-97-00

Syros Pharmaceuticals Inc.Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

End: 2024-11-12Target: 417Updated: 2024-11-27